drugset / Trial / NCT01134185

Evaluation of Prucalopride in Subjects With Moderate and Severe Hepatic Impairment

NCT01134185

Phase 1 Completed 24 enrolled Movetis
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a single centre, open-label phase I trial to investigate the effects of moderate to severe hepatic impairment on the pharmacokinetics of prucalopride in comparison with healthy volunteers. Furthermore the short-term safety and tolerability of a single dose of prucalopride will be assessed.

Timeline

Start
2010-05
Primary completion
2011-02
Completion
2011-02

Drugs

EvaluationDrugModalityDoseRoute
Comparator Prucalopride Small molecule 2 mg Oral

Indications

No indication recorded.